Tetrahydrocannabinol similar in efficacy & safety as placebo in improving spasticity and pain in MS

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:N/A

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis

Clin Ther. 2018 Sep;40(9):1467-1482. doi: 10.1016/j.clinthera.2017.01.016

Contributing Authors: G van Amerongen K Kanhai AC Baakman J Heuberger E Klaassen TL Beumer RLM Strijers J Killestein J van Gerven A Cohen GJ Groeneveld

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Explore some of our unlocked reports below!

Comparison of safety between endoscopic and open carpal tunnel release

Benefit of specific vs general exercise for low back pain with movement control impairment

Comparing clinical and radiographic outcomes of stemless vs stemmed implants in TSA

Comparing knee stability, subjective function, and OA development between DB & SB ACL reconstruction

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.

Tetrahydrocannabinol similar in efficacy & safety as placebo in improving spasticity and pain in MS

To view the full report, start your 30-day free trial today

Explore some of our unlocked reports below!

Continuing Medical Education Credits

Please be patient while we setup your OrthoEvidence account.

Please be patient
while we setup your
OrthoEvidence account.